Literature DB >> 1998989

Measurement of in vitro cellular pharmacokinetics of 5-fluorouracil in human and rat cancer cell lines and rat hepatocytes using a flow-through system.

E C Spoelstra1, H M Pinedo, H Dekker, G J Peters, J Lankelma.   

Abstract

A flow-through system was used to study the cellular pharmacokinetics of 5-fluorouracil (5-FU) in four human cell lines (squamous-cell carcinoma HEp-2, colon carcinoma WiDr, hepatoma Hep G2, and breast carcinoma MCF-7) as well as in the rat hepatoma H35 cell line and in freshly isolated rat hepatocytes. The system made it possible to restrict the decrease in the concentration of 5-FU in the medium, to keep the volume in which the metabolites accumulated relatively small, and to study the dynamics of a response during and after a change in the composition of the eluent. Clearance of 5-FU from the eluent was achieved predominantly (greater than 95%) by its catabolism to dihydrofluorouracil in the tumor cell lines and to 2-fluoro-beta-alanine in the hepatocytes. Not only rat hepatocytes but also HEp-2 cells showed relatively high clearance values. A concentration-dependent 5-FU elimination was observed, indicating saturation of 5-FU elimination according to Michaelis-Menten kinetics (Km 14-22 microM). The maximal velocity (Vmax) values ranged from 0.025 to 0.13 nmol 5-FU/10(6) cells per minute. For HEp-2 cells, high-concentration pulse injections of 5-FU, thymine, uridine, or uracil immediately led to a reduction in 5-FU conversion, followed by recovery within 5 min. The flow-through system proved to be adequate for the study of the non-linear pharmacokinetics of 5-FU in different intact cells and for the comparison of various manipulations of these pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1998989     DOI: 10.1007/bf00685119

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  30 in total

1.  Pyrimidine base degradation in cultured murine C-1300 neuroblastoma cells and in situ tumors.

Authors:  M Tuchman; R F O'Dea; M L Ramnaraine; B L Mirkin
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

Review 2.  The pharmacology of the fluoropyrimidines.

Authors:  C E Myers
Journal:  Pharmacol Rev       Date:  1981-03       Impact factor: 25.468

3.  Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high performance liquid chromatography.

Authors:  J P Sommadossi; D A Gewirtz; R B Diasio; C Aubert; J P Cano; I D Goldman
Journal:  J Biol Chem       Date:  1982-07-25       Impact factor: 5.157

4.  Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil, and thymine by rat liver dihydropyrimidine dehydrogenase.

Authors:  M Tuchman; M L Ramnaraine; R F O'Dea
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

5.  A mathematical model of the kinetics of 5-fluorouracil and its catabolites in freshly isolated rat hepatocytes.

Authors:  F Mentre; J L Steimer; J P Sommadossi; R B Diasio; J P Cano
Journal:  Biochem Pharmacol       Date:  1984-09-01       Impact factor: 5.858

6.  Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule.

Authors:  C J van Groeningen; H M Pinedo; J Heddes; R M Kok; A P de Jong; E Wattel; G J Peters; J Lankelma
Journal:  Cancer Res       Date:  1988-12-01       Impact factor: 12.701

7.  Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes.

Authors:  G J Peters; E Laurensse; A Leyva; J Lankelma; H M Pinedo
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

8.  Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen.

Authors:  B B Knowles; C C Howe; D P Aden
Journal:  Science       Date:  1980-07-25       Impact factor: 47.728

9.  Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients.

Authors:  L J Schaaf; B R Dobbs; I R Edwards; D G Perrier
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes.

Authors:  J M Collins; R L Dedrick; F G King; J L Speyer; C E Myers
Journal:  Clin Pharmacol Ther       Date:  1980-08       Impact factor: 6.875

View more
  1 in total

1.  Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma.

Authors:  G J Peters; J Lankelma; R M Kok; P Noordhuis; C J van Groeningen; C L van der Wilt; S Meyer; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.